Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-28 00:52:02 - browse：653

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Hospitals are dialing back on venture capital investing

focus

WSS

YouTube cracks down on misinformation on cancer treatment

Neuroscience’s long legacy of racism

AstraZeneca to buy developer of next

U.K. researchers warn about biases in medical devices, algorithms

Asbestos, a deadly carcinogen, banned by EPA

Biogen’s boardroom scandal saddles CEO with first crisis

explore

Wikipedia

Wikipedia

New air purifier tech could be key to improving indoor air quality

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Duchenne breakthrough therapy leaves behind pioneering families

Biogen’s boardroom scandal saddles CEO with first crisis

As demand for Covid shots wanes, Moderna seeks its next success

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Medical records are filled with copy

UnitedHealth increases loan offers after Change Healthcare outage

Trump demands the U.S. pay no more for drugs than other countries … again

Surge in Apellis stock fueled by confidence in safety of its eye drug

hotspot

Idaho college killings prosecutors challenge defense's grand jury claims

Judge sides with young activists in first

Biogen’s boardroom scandal saddles CEO with first crisis

Be careful with at

Surge in Apellis stock fueled by confidence in safety of its eye drug

Treatments for cramps don't cut it. Why aren't there better options?

hotspot

focus

focus

leisure time